July 8, 2021
Bayer Yakuhin said on July 7 that it has launched its oral tropomyosin receptor kinase (TRK) inhibitor Vitrakvi Capsules (larotrectinib) in Japan for the treatment of neurotrophic TRK (NTRK) fusion-positive advanced or relapsed solid tumors. Vitrakvi was approved in March...read more